Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 68001-105

6 FDA label images from Bluepoint Laboratories · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 68001-105). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Structural Formula (Divalproexertablet Figure 01)

Structural Formula (Divalproexertablet Figure 01)
Chemical structure of Divalproex Sodium depicting its molecular arrangement, including carbon chains, sodium ion, and carboxylate groups, consistent with the active ingredient in the product.*
FDA Label Image

Figure 1 (Divalproexertablet Figure 02)

Figure 1 (Divalproexertablet Figure 02)
A line graph comparing the percentage reduction in CPS rate between Divalproex Sodium delayed-release tablets and placebo over a range of patient percentages. The Y-axis shows percentage reduction in CPS rate from -100% (worsening) to 100% (improvement), while the X-axis represents the percentage of patients from 100% to 0%. The solid line represents Divalproex Sodium, showing greater improvement compared to the dashed line for placebo.*
FDA Label Image

Figure 2 (Divalproexertablet Figure 03)

Figure 2 (Divalproexertablet Figure 03)
A line graph illustrating the percentage reduction in CPS rate versus the percentage of patients for Divalproex Sodium delayed-release tablets. Two curves compare high dose (solid line) and low dose (dashed line) formulations, showing patient improvement and worsening outcomes across doses.*
FDA Label Image

Figure 3 (Divalproexertablet Figure 04)

Figure 3 (Divalproexertablet Figure 04)
A bar chart comparing placebo to Divalproex Sodium Extended-release Tablets. The y-axis ranges from 0.0 to 1.2, showing a value of 0.6 for placebo and 1.2 for Divalproex Sodium Extended-release Tablets. A note indicates statistical significance at p=0.006.*
FDA Label Image

Divalproex Sodium Er Tablets 250mg 100tablets Rev 04-17 (Image 01)

Divalproex Sodium Er Tablets 250mg 100tablets Rev 04-17 (Image 01)
Packaging label for Divalproex Sodium Extended-release Tablets, USP, 250 mg strength by BluePoint Laboratories. The label indicates once-daily dosing and contains 100 tablets. It includes storage instructions, dosage forms, and dispensing guidelines with a blue and white color scheme featuring the BluePoint Laboratories logo.*
FDA Label Image

Divalproex Sodium Er Tablets 500mg 100tablets Rev 04-17 (Image 02)

Divalproex Sodium Er Tablets 500mg 100tablets Rev 04-17 (Image 02)
Label for Divalproex Sodium extended-release tablets, USP, 500 mg strength by BluePoint Laboratories. The label indicates once-daily dosing, packaging 100 film-coated tablets. It includes storage instructions (20-25°C), medication guide availability, and pharmacist dispensing information. The NDC code 68001-106-00 is visible along with the label revision date 03/21.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.